Nov. 3, 2014
SCYNEXIS Inc. announced on Nov. 3, 2014 that it has entered into a licensing agreement granting Waterstone Pharmaceutical (HK) Limited exclusive worldwide rights to develop and commercialize SCY-635 for the treatment of viral diseases in humans.
SCY-635 is a cyclophilin inhibitor which has shown promise in treating viral infections through its selective targeting of host proteins.
Under the terms of the agreement, Waterstone has worldwide development and commercialization rights to SCY-635 for the treatment of human viral diseases, as well as the option to license two additional cyclophilin inhibitors from SCYNEXIS. SCYNEXIS will receive an upfront payment and is entitled to certain commercialization milestones and royalties.